Press Releases

January 30 2014

Patients Should Be Informed if Doctor's Prescription Changed

November 18 2013

BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.

July 29 2013

BIO released a statement in support of the FDA Safety Over Sequestration Act (H.R. 2725), which...

February 9 2012

BIO President and CEO Jim Greenwood issued the following statement regarding the newly...

February 1 2012

In the testimony, Richard Pops, Alkermes plc Chairman and CEO,  stressed the...

October 4 2011

A coalition of anti-technology groups under the moniker “Just Label It” has...

September 1 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

August 3 2011

Animal Agriculture Coalition Members denounce political interference in FDA process.

July 27 2011

BIO praised today’s ruling by a U.S. District Court dismissing a lawsuit that sought to...

June 29 2011

“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease...

June 16 2011

An amendment offered on the House floor last night would ban the FDA from using any funding to...

August 26 2010

Genetically engineered (GE) animals have already realized the promise of advancing human...

March 22 2010

U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg will be a featured...

March 15 2009

BIO President and CEO Jim Greenwood released the following statement today commending President...

September 19 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

February 4 2013
BIO thanks the Food and Drug Administration (FDA) for the opportunity to provide comments on the proposal to create an alternative approval pathway for certain drugs intended to address unmet medical need, also referred to as a Special Medical Use (SMU) designation.
January 22 2013
BIO thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for IRBs, Clinical Investigators, and Sponsors."
January 22 2013
BIO thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Development of Prioritized Therapeutic Data Standards (the Notice).”
August 6 2014
Survey responses will help inform Prescription Drug User Fee Act VI negotiations
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed
November 18 2013
BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.
July 29 2013
BIO released a statement in support of the FDA Safety Over Sequestration Act (H.R. 2725), which would exempt user fees, including those paid by BIO member companies, from the operation of sequestration.
February 9 2012
BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.